Soluble ST2 and N-terminal pro-brain natriuretic peptide combination: Useful biomarker for predicting outcome of childhood pulmonary arterial hypertension

Circulation Journal

Volumn 78, Issue 2, 2014, Pages 436-442

  Chida, Ayako ^a,b   Sato, Hiroki ^a   Shintani, Masaki ^b   Nakayama, Tomotaka ^c   Kawamura, Yoichi ^a   Furutani, Yoshiyuki ^b   Inai, Kei ^b   Saji, Tsutomu ^c   Matsuoka, Rumiko ^b,d   Nonoyama, Shigeaki ^a   Nakanishi, Toshio ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^d TOHO UNIVERSITY   (Japan)

Author keywords

Biomarker; Childhood pulmonary arterial hypertension; N terminal pro brain natriuretic peptide; Prognosis; Soluble ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOPOIETIN 2; BIOLOGICAL MARKER; ENDOSTATIN; FATTY ACID BINDING PROTEIN; GELATINASE A; PENTRAXIN 3; SOLUBLE ST2 PROTEIN; TENASCIN; THYMIDINE KINASE; TROPONIN T; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; CHILD; CLINICAL EVALUATION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEMODYNAMIC PARAMETERS; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PROGNOSIS; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL; ADOLESCENT; BLOOD; CLINICAL TRIAL; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 84892957779     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1033     Document Type: Article

References (28)

1. Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63: 321-327.
2. Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009; 135: 745-751.
3. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2009; 135: 21-26.
4. Takatsuki S, Wagner BD, Ivy DD. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 2012; 7: 259-267.
5. Schumann C, Lepper PM, Frank H, Schneiderbauer R, Wibmer T, Kropf C, et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers 2010; 15: 523-532.
6. Kümpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM, et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31: 2291-2300.
7. Tamura Y, Ono T, Kuwana M, Inoue K, Takei M, Yamamoto T, et al. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS One 2012; 7: e45834.
8. Satoh K, Fukumoto Y, Sugimura K, Miura Y, Aoki T, Nochioka K, et al. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J 2013; 77: 447-455.
9. Carlomagno G, Messalli G, Melillo RM, Stanziola AA, Visciano C, Mercurio V, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol 2013; 168: 1545-1547.
10. Fujiwara M, Yagi H, Matsuoka R, Akimoto K, Furutani M, Imamura S, et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008; 72: 127-133.
11. Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009; 46: 331-337.
12. Chida A, Shintani M, Nakayama T, Furutani Y, Hayama E, Inai K, et al. Missense mutations of BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension. Circ J 2012; 76: 1501-1508.
13. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
14. O'Neill L. The Toll/interleukin-1 receptor domain: A molecular switch for inflammation and host defence. Biochem Soc Trans 2000; 28: 557-563.
15. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002; 14: 117-122.
16. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2966.
17. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham Heart Study. Circulation 2012; 126: 1596-1604.
18. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009; 2: 684-691.
19. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003; 107: 721-726.
20. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008; 117: 1936-1944.
21. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, Vázquez R, Puig T, Valdés M, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009; 54: 2174-2179.
22. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011; 107: 259-267.
23. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T-and N-terminal pro-B-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13: 718-725.
24. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009; 2: 311-319.
25. Sato YZ, Molkara DP, Daniels LB, Tremoulet AH, Shimizu C, Kanegaye JT, et al. Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol 2013; 164: 58-63.
26. Willems S, Sels JW, Flier S, Versteeg D, Buhre WF, de Kleijn DP, et al. Temporal changes of soluble ST2 after cardiovascular interventions. Eur J Clin Invest 2013; 43: 113-120.
27. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
28. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-208.